vs
Side-by-side financial comparison of REGENXBIO Inc. (RGNX) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.
RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $30.3M, roughly 1.2× REGENXBIO Inc.). REGENXBIO Inc. runs the higher net margin — -221.3% vs -304.2%, a 82.9% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 43.0%). RECURSION PHARMACEUTICALS, INC. produced more free cash flow last quarter ($-47.3M vs $-52.8M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 39.4%).
REGENXBIO Inc. is a clinical-stage biotechnology firm focused on gene therapy for rare severe genetic diseases. It licenses its proprietary AAV vector technology to global biopharma partners, and advances its own pipeline targeting ophthalmology, metabolic and neurodegenerative disorders.
Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.
RGNX vs RXRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.3M | $35.5M |
| Net Profit | $-67.1M | $-108.1M |
| Gross Margin | — | 59.8% |
| Operating Margin | -190.0% | -304.8% |
| Net Margin | -221.3% | -304.2% |
| Revenue YoY | 43.0% | 681.7% |
| Net Profit YoY | -31.2% | 39.6% |
| EPS (diluted) | $-1.30 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.3M | $35.5M | ||
| Q3 25 | $29.7M | $5.2M | ||
| Q2 25 | $21.4M | $19.2M | ||
| Q1 25 | $89.0M | $14.7M | ||
| Q4 24 | $21.2M | $4.5M | ||
| Q3 24 | $24.2M | $26.1M | ||
| Q2 24 | $22.3M | $14.4M | ||
| Q1 24 | $15.6M | $13.8M |
| Q4 25 | $-67.1M | $-108.1M | ||
| Q3 25 | $-61.9M | $-162.3M | ||
| Q2 25 | $-70.9M | $-171.9M | ||
| Q1 25 | $6.1M | $-202.5M | ||
| Q4 24 | $-51.2M | $-178.9M | ||
| Q3 24 | $-59.6M | $-95.8M | ||
| Q2 24 | $-53.0M | $-97.5M | ||
| Q1 24 | $-63.3M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | 70.2% | -181.4% | ||
| Q3 24 | 48.8% | 53.7% | ||
| Q2 24 | 52.5% | 36.2% | ||
| Q1 24 | 72.6% | 19.1% |
| Q4 25 | -190.0% | -304.8% | ||
| Q3 25 | -176.3% | -3327.6% | ||
| Q2 25 | -296.3% | -916.8% | ||
| Q1 25 | 13.6% | -1297.9% | ||
| Q4 24 | -242.1% | -4042.4% | ||
| Q3 24 | -256.6% | -377.1% | ||
| Q2 24 | -251.3% | -697.4% | ||
| Q1 24 | -408.8% | -698.4% |
| Q4 25 | -221.3% | -304.2% | ||
| Q3 25 | -208.3% | -3135.3% | ||
| Q2 25 | -331.8% | -894.2% | ||
| Q1 25 | 6.8% | -1373.3% | ||
| Q4 24 | -241.3% | -3935.5% | ||
| Q3 24 | -246.3% | -367.5% | ||
| Q2 24 | -237.7% | -676.6% | ||
| Q1 24 | -405.4% | -662.4% |
| Q4 25 | $-1.30 | $-0.17 | ||
| Q3 25 | $-1.20 | $-0.36 | ||
| Q2 25 | $-1.38 | $-0.41 | ||
| Q1 25 | $0.12 | $-0.50 | ||
| Q4 24 | $-0.99 | $-0.56 | ||
| Q3 24 | $-1.17 | $-0.34 | ||
| Q2 24 | $-1.05 | $-0.40 | ||
| Q1 24 | $-1.38 | $-0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $230.1M | $743.3M |
| Total DebtLower is stronger | — | $9.6M |
| Stockholders' EquityBook value | $102.7M | $1.1B |
| Total Assets | $453.0M | $1.5B |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.1M | $743.3M | ||
| Q3 25 | $274.2M | $659.8M | ||
| Q2 25 | $323.3M | $525.1M | ||
| Q1 25 | $267.9M | $500.5M | ||
| Q4 24 | $234.7M | $594.4M | ||
| Q3 24 | $255.5M | $427.6M | ||
| Q2 24 | $290.4M | $474.3M | ||
| Q1 24 | $338.7M | $296.3M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | $102.7M | $1.1B | ||
| Q3 25 | $161.5M | $1.0B | ||
| Q2 25 | $213.7M | $919.1M | ||
| Q1 25 | $274.2M | $933.9M | ||
| Q4 24 | $259.7M | $1.0B | ||
| Q3 24 | $301.4M | $524.6M | ||
| Q2 24 | $348.3M | $584.4M | ||
| Q1 24 | $390.7M | $401.2M |
| Q4 25 | $453.0M | $1.5B | ||
| Q3 25 | $525.2M | $1.4B | ||
| Q2 25 | $581.0M | $1.3B | ||
| Q1 25 | $490.9M | $1.3B | ||
| Q4 24 | $466.0M | $1.4B | ||
| Q3 24 | $519.1M | $726.5M | ||
| Q2 24 | $569.4M | $775.9M | ||
| Q1 24 | $629.2M | $557.8M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.3M | $-46.1M |
| Free Cash FlowOCF − Capex | $-52.8M | $-47.3M |
| FCF MarginFCF / Revenue | -174.0% | -133.1% |
| Capex IntensityCapex / Revenue | 1.7% | 3.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-126.4M | $-378.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.3M | $-46.1M | ||
| Q3 25 | $-56.0M | $-117.4M | ||
| Q2 25 | $-49.3M | $-76.4M | ||
| Q1 25 | $33.6M | $-132.0M | ||
| Q4 24 | $-31.6M | $-115.4M | ||
| Q3 24 | $-40.5M | $-59.2M | ||
| Q2 24 | $-45.5M | $-82.2M | ||
| Q1 24 | $-55.5M | $-102.3M |
| Q4 25 | $-52.8M | $-47.3M | ||
| Q3 25 | $-56.5M | $-117.6M | ||
| Q2 25 | $-49.7M | $-79.6M | ||
| Q1 25 | $32.6M | $-133.8M | ||
| Q4 24 | $-32.7M | $-116.7M | ||
| Q3 24 | $-40.9M | $-63.8M | ||
| Q2 24 | $-46.0M | $-83.4M | ||
| Q1 24 | $-56.0M | $-109.0M |
| Q4 25 | -174.0% | -133.1% | ||
| Q3 25 | -189.9% | -2272.5% | ||
| Q2 25 | -232.8% | -413.9% | ||
| Q1 25 | 36.6% | -907.4% | ||
| Q4 24 | -154.2% | -2567.7% | ||
| Q3 24 | -168.9% | -244.6% | ||
| Q2 24 | -206.2% | -578.5% | ||
| Q1 24 | -358.5% | -789.9% |
| Q4 25 | 1.7% | 3.5% | ||
| Q3 25 | 1.7% | 4.7% | ||
| Q2 25 | 1.8% | 16.4% | ||
| Q1 25 | 1.2% | 12.4% | ||
| Q4 24 | 5.1% | 28.6% | ||
| Q3 24 | 1.3% | 17.5% | ||
| Q2 24 | 2.1% | 8.2% | ||
| Q1 24 | 3.6% | 48.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 5.53× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
RXRX
Segment breakdown not available.
